과민성장증후군 치료 시장 보고서 : 유형, 제품, 유통 채널, 지역별(2024-2032년)

The global irritable bowel syndrome treatment market size reached US$ 2.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.5 Billion by 2032, exhibiting a growth rate (CAGR) of 8% during 2024-2032.

Irritable bowel syndrome (IBS) refers to a chronic medical condition that affects the large intestine. It is usually caused by severe infection, stressful lifestyle, changes in gut microbes, muscle contractions in the intestine, and abnormalities in the nervous system. It can be characterized by gas, diarrhea, cramping, bloating, constipation, weight loss, vomiting, abdominal pain, and difficulty in swallowing. Several medications are currently available to relieve mild symptoms of IBS, including rifaximin, loperamide, laxatives, antispasmodics, fiber supplements, and coated peppermint oil capsules. Doctors also recommend probiotics and mental health therapies, such as cognitive behavioral-therapy (CBT), gut-directed hypnotherapy, and relaxation training, to treat certain patients

Irritable Bowel Syndrome Treatment Market Trends:

Several factors increase the risk of IBS diseases, including food intolerances or sensitivities, bacterial infections in the digestive tract, small intestinal bacterial overgrowth, and mental disorders like anxiety, depression, and somatic symptom. This, along with improving diagnostic modalities and easy access to healthcare services, represents one of the key factors bolstering the growth of the market. Furthermore, IBS is one of the most common functional gastrointestinal disorders among the elderly. In confluence with this, the rising geriatric population across the globe is influencing the market positively. Besides this, several clinical trials, such as fecal microbiota transplantation (FMT), are being conducted to improve the treatment of IBS, which is contributing to market growth. In addition to this, as part of the Sustainable Development Goals (SDGs), governing agencies of various countries have pledged to substantially increase spending on research and development (R&D) projects and the number of researchers by 2030. This, in turn, is projected to expand the number of potential treatment options for IBS in the future.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global irritable bowel syndrome treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, product and distribution channel.

Breakup by Type:

IBS with Diarrhea (IBS-D)

IBS with Constipation (IBS-C)

Mixed IBS

Breakup by Product:

Rifaximin

Eluxadoline

Lubiprostone

Linaclotide

Others

Breakup by Distribution Channel:

Hospitals Pharmacies

Drug Stores and Retail Pharmacies

Online Stores

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Allergan plc (AbbVie Inc.), Ardelyx Inc., Astellas Pharma Inc., AstraZeneca plc, Bausch Health Companies Inc., GlaxoSmithKline Plc, Novartis AG, Sebela Pharmaceuticals Inc., Synthetic Biologics Inc. and Takeda Pharmaceutical Company Limited.

Key Questions Answered in This Report:

• How has the global irritable bowel syndrome treatment market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global irritable bowel syndrome treatment market?
• What are the key regional markets?
• What is the breakup of the market based on the type?
• What is the breakup of the market based on the product?
• What is the breakup of the market based on the distribution channel?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global irritable bowel syndrome treatment market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Irritable Bowel Syndrome Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 IBS with Diarrhea (IBS-D)
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 IBS with Constipation (IBS-C)
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Mixed IBS
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Product

• 7.1 Rifaximin
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Eluxadoline
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Lubiprostone
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Linaclotide
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospitals Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Drug Stores and Retail Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Online Stores
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Allergan plc (AbbVie Inc.)
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Ardelyx Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
  • 14.3.4 Astellas Pharma Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 AstraZeneca plc
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Bausch Health Companies Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 GlaxoSmithKline Plc
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Novartis AG
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Sebela Pharmaceuticals Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Synthetic Biologics Inc.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
  • 14.3.11 Takeda Pharmaceutical Company Limited
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis